• Maria Dafni, Maria Karampeli, Ioannis Michelakis, Aspasia Manta, Anastasia Spanoudaki, Dionysios Mantzos, Sofia Krontira, Victoria Georgiadou, Athina Lioni, and Vasiliki Tzavara.
• 1st Department of Internal Medicine, Korgialenio-Benakio Red Cross General Hospital, Athens, Greece.
• J. Investig. Med. 2022 Aug 1; 70 (6): 142314281423-1428.

AbstractSince the outbreak of COVID-19, research has been focused on establishing effective treatments, especially for patients with severe pneumonia and hyperinflammation. The role and dose of corticosteroids remain obscure. We evaluated 58 patients with severe COVID-19 during two periods. 24 patients who received methylprednisolone pulses (250 mg/day intravenously for 3 days) were compared with 34 patients treated according to the standard dexamethasone protocol of 6 mg/day. Among non-intubated patients, the duration of hospitalization was shorter for those who received methylprednisolone pulses (9.5 vs 13.5, p<0.001). In a subgroup analysis of patients who required intubation, those treated with the dexamethasone protocol demonstrated a relative risk=1.89 (p=0.09) for dying, in contrast to the other group which showed a tendency towards extubation and discharge from the hospital. A 'delayed' need for intubation was also observed (6 vs 2 days, p=0.06). Treatment with methylprednisolone pulses significantly reduced hospitalization time. Although there was no statistically significant influence on the necessity for intubation, methylprednisolone pulses revealed a tendency to delay intubation and hospital discharges. This treatment could benefit patients in the hyperinflammatory phase of the disease.© American Federation for Medical Research 2022. No commercial re-use. See rights and permissions. Published by BMJ.

12 keywords...

hide…